Table 2.

HLA alleles in patients with MOGADs and in healthy controls

HLA allele	Patients (n=95 × 2)			Controls (n=481 × 2)			P value	Padj value	OR (95% CI)
	Positive	Negative	Freq	Positive	Negative	Freq
DQB1*05:02	36	154	0.1895	103	859	0.1071	0.0023	0.0316	1.95 (1.25 to 3.00)
DPB1*13:01	7	183	0.0368	82	880	0.0852	0.0246	0.1105	0.41 (0.16 to 0.91)
DRB1*08:03	4	186	0.0211	69	893	0.0717	0.0055	0.1278	0.28 (0.07 to 0.76)
DRB1*16:02	17	173	0.0895	41	921	0.0426	0.0106	0.1278	2.21 (1.15 to 4.08)
DPA1*02:02	124	66	0.6526	550	412	0.5717	0.0438	0.1754	1.41 (1.01 to 1.98)
DQA1*01:02	51	139	0.2684	192	770	0.1996	0.0407	0.2215	1.47 (1.01 to 2.13)
DQA1*01:03	7	183	0.0368	79	883	0.0821	0.0332	0.2215	0.43 (0.16 to 0.94)
DRB1*14:05	8	182	0.0421	16	946	0.0166	0.0446	0.2675	2.60 (0.95 to 6.54)
DRB1*15:02	11	179	0.0579	26	936	0.0270	0.0397	0.2675	2.21 (0.97 to 4.73)
DQB1*05:03	15	175	0.0789	40	922	0.0416	0.0385	0.2697	1.97 (0.99 to 3.75)
C*07:02	22	168	0.1158	171	791	0.1778	0.0429	0.3144	0.61 (0.36 to 0.98)
C*06:02	2	188	0.0105	38	924	0.0395	0.0493	0.3144	0.26 (0.03 to 1.02)
A*02:07	34	156	0.1789	119	843	0.1237	0.0465	0.4683	1.54 (0.98 to 2.37)

Table shows only HLA alleles with an unadjusted p value of <0.05. P values are adjusted for multiple testing via the FDR step-up method.

FDR, false discovery rate; freq, frequency; HLA, human leucocyte antigen; MOGADs, myelin oligodendrocyte glycoprotein-associated disorders.